OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Haberl, Connor Lucas
Redpath, Calum Jon
Crean, Andrew Michael
Dekemp, Robert Anthony
Abrégé
The system described herein includes a tool that has been developed for the interactive planning of therapies (e.g., ablation therapies such as RA in the treatment of VT or catheter- based therapies, among many others) by accurately registering all treatment planning images into the same frame-of-reference, to enable physician interaction with different image visualizations of these registered images, including ablation target selection, to provide an environment that facilitates the efficient and accurate exchange of knowledge between physicians. The proposed tool is provided to increase access, expedite delivery, and improve target accuracy for various therapies, including the non-limiting example described below which provides an innovative non-invasive VT ablation therapy.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G06T 7/30 - Détermination des paramètres de transformation pour l'alignement des images, c.-à-d. recalage des images
2.
PEPTIDES, HYDROGELS, PHOTOACTIVATABLE HYDROGEL PRECURSORS, METHODS OF PREPARATION AND DEVICES FOR DELIVERY THEREOF, AND METHODS OF TREATMENT THEREWITH
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Alarcon, Emilio I.
Macadam, Aidan
Ross, Alex
Suuronen, Erik J.
Ruel, Marc
Comtois-Bona, Maxime
Guo, Xixi
Salazar, Andres Mercado
Schejtman, Sergio David Garcia
Guzman-Soto, Irene
Muñoz, Marcelo
Abrégé
Provided herein are self-assembling collagen-like peptide (CLP) comprising a plurality of amino acid trimer repeats having the amino acid sequence POG, wherein P is a proline, O is an hydroxyproline or a cysteine, and G is a glycine or a valine. Also provided herein are compositions, scaffolds, photoactivatable hydrogel precursors and hydrogels comprising the CLP and a multi-arm polyethylene glycol (PEG) polymer. Methods of preparing photoactivatable hydrogel precursors and hydrogels are also described. Methods of treating a wound, of treating a corneal disease, of treating a myocardial infarct, of promoting cell growth and of treating cellular degeneration using the compositions, scaffolds, photoactivatable hydrogel precursors and/or hydrogels are also described. Also provided is a device for delivering a peptide-based material. The device comprises an on/off button or switch for initiating and stopping delivery of the peptide-based material in the subject; a chamber for containing the peptide-based material; an aperture through which the peptide-based material exits the chamber, wherein the aperture is adapted for receiving a nozzle adapter; a camera port for securing a camera thereto; and a digital control display.
A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Lefort, Etienne
Teoli, Vincenzo
Dekemp, Robert A.
Klein, Ran
Abrégé
Provided are 82Sr/82Rb elution systems that accept patient weight as a input function in order to determine an optimal quantity of radioactive rubidium-82 for delivery to a patient pursuant to an imaging scan. Also disclosed are systems that deliver a saline flush to remove residual 82Rb from the system downstream of the generator, and preferably deliver the removed residual 82Rb to the patient. Other disclosed systems measure the total volume of saline that flows through a 82Sr/82Rb generator, a total volume of saline that flows through the generator and through a bypass line, or a total volume of saline received by a waste reservoir, in order to monitor system components so that optimal system functioning is assured.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Casey, Michael E.
Dekemp, Robert
Abrégé
A system and method include acquisition of emission data from an object while a radioactive tracer is present in the object, determination of first parameters of a first Gaussian distribution representing a positron range distribution of the radioactive tracer, determination of second parameters of a second Gaussian distribution associated with imaging characteristics of the imaging system, generation of a system matrix based on the first parameters and the second parameters, reconstruction of a three-dimensional image based on the emission data and the system matrix, and display of the three-dimensional image.
G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p. ex. sur la position ou la section du faisceauMesure de la distribution spatiale de radiations
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Dekemp, Robert A.
Abrégé
18F. The radioisotope is infused in the subject for imaging of the heart using Positron Emission Tomography imaging. The methods confer improved image quality with low background noise, higher signal to noise ratio (SNR) and higher contrast to noise ratio (CNR), leading to better diagnosis and thus eliminating the need of repeating the infusion and imaging which in turn reduces exposure of a patient to radiation.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
7.
PEPTIDES AND HYDROGELS FOR TREATING CORNEAL DISEASES
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
RSEM, LIMITED PARTNERSHIP (Canada)
Inventeur(s)
Alarcon Abarzua, Emilio Isaac
Munoz Figueroa, Marcelo Alejandro
Vilé Macadam, Aidan James
Ross, Alex
Grenier, Michel
Griffith, May
Brunette, Isabelle
Abrégé
Provided herein are photosensitive bulking agent (PBA) comprising a photoreactive collagen-like peptide (PCLP) and polyethylene glycol (PEG). Also provided herein are compositions, scaffolds, precursor hydrogels and hydrogels comprising the PBA and methods of preparation thereof. Photoreactive collagen-like peptides comprising photoreactive residues are also provided herein. Compositions comprising photoreactive collagen-like peptides that are not crosslinked, partially crosslinked and fully crosslinked are provided as well as uses thereof for treating, preventing, or augmenting corneal thinning or any other corneal defects in a subject in need thereof. A method of treating a condition of the eye characterized by a corneal defect is also described herein. The method comprises making a limbal incision in an area affected by the corneal defect in a subject, administering a precursor hydrogel over the corneal defect, and irradiating the precursor hydrogel with visible light.
A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Sun, Louise Ying Pw
Abrégé
A system and method are provided for predicting hemodynamic events. The method includes receiving current patient data, obtaining a current mean arterial pressure (MAP) value from the current patient data, and obtaining prior MAP data obtained from the patient during a period of care. The method also includes using the current MAP value, the past MAP data, a predetermined MAP threshold, and at least one trained model to predict a hemodynamic event, each trained model corresponding to a prediction interval to determine whether the hemodynamic event is expected to occur within a window of time; and outputting an alert indicative of the hemodynamic event to a device configured to display a graphical user interface comprising the alert.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Lefort, Etienne
Teoli, Vicenzo
Dekemp, Robert A.
Klein, Ran
Abrégé
Embodiments of the present invention provide for assessing the state of an 82Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 82Rb, 82Sr, or 85Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 82Sr/82Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the 82Rb elution system.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Casey, Michael, E.
Dekemp, Robert
Abrégé
A system and method include acquisition of emission data from an object while a radioactive tracer is present in the object, determination of first parameters of a first Gaussian distribution representing a positron range distribution of the radioactive tracer, determination of second parameters of a second Gaussian distribution associated with imaging characteristics of the imaging system, generation of a system matrix based on the first parameters and the second parameters, reconstruction of a three-dimensional image based on the emission data and the system matrix, and display of the three-dimensional image.
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Dekemp, Robert A.
Abrégé
The present invention provides an improved method of PET imaging in a subject for diagnosis and/or treatment of cardiovascular related disease. The method comprises exponential function dosing based on subject body habitus. It provides improved and consistent imaging quality in comparison to fixed or linear dosing based on subject's body weight. More particularly, it relates to a method of imaging processing for diagnosing and/or identifying a risk of developing a coronary artery disease comprising administering a dose of Rb-82 to a subject, wherein the dose is calculated based on exponential squared function of body habitus of the subject; and wherein the method of imaging processing in a subject is iterative ordered-subset expectation maximization (OSEM) reconstruction method.
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Dekemp, Robert A.
Abrégé
Disclosed are methods of radioisotope infusion comprising infusing saline comprising a diagnostic dose of a radioisotope, and delivering a pre-measured volume of push saline. The disclosed methods confer improved image quality with low background noise, higher signal to noise ratio (SNR) and higher contrast to noise ratio (CNR), leading to better diagnosis and thus eliminating the need of repeating the infusion and imaging which in turn reduces exposure of a patient to radiation.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES (Canada)
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Sun, Louise
Abrégé
Systems and methods for managing health related resources. A length of stay (LOS) module and a waitlist module receive patient data from a database and, based on at least this data, determine probabilities for one or more patients. For the LOS module, the probability of staying for less than 2 days or more than 7 days after a specific type of surgical procedure is determined. For the waitlist module, the probability of the patient dying or becoming hospitalized within a specific amount of time while on a waiting list is determined. These probabilities are then used by a resource management module to adjust or reallocate health related resources such as critical care slots or surgical procedure scheduling.
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
14.
SYSTEMS, METHODS AND APPARATUS FOR PREDICTING HEMODYNAMIC EVENTS
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Sun, Louise Ying Pw
Abrégé
A system and method are provided for predicting hemodynamic events. The method includes receiving current patient data, obtaining a current mean arterial pressure (MAP) value from the current patient data, and obtaining prior MAP data obtained from the patient during a period of care. The method also includes using the current MAP value, the past MAP data, a predetermined MAP threshold, and at least one trained model to predict a hemodynamic event, each trained model corresponding to a prediction interval to determine whether the hemodynamic event is expected to occur within a window of time; and outputting an alert indicative of the hemodynamic event to a device configured to display a graphical user interface comprising the alert.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
15.
IMPROVED DOSING METHOD FOR POSITRON EMISSION TOMOGRAPHY IMAGING
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Dekemp, Robert A.
Abrégé
The present invention provides an improved method of PET imaging in a subject for diagnosis and/or treatment of cardiovascular related disease. The method comprises exponential function dosing based on subject body habitus. It provides improved and consistent imaging quality in comparison to fixed or linear dosing based on subject's body weight.
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p. ex. sur la position ou la section du faisceauMesure de la distribution spatiale de radiations
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Lefort, Etienne
Teoli, Vincenzo
Dekemp, Robert A.
Klein, Ran
Abrégé
Provided are 82Sr/82Rb elution systems that accept patient weight as a input function in order to determine an optimal quantity of radioactive rubidium-82 for delivery to a patient pursuant to an imaging scan. Also disclosed are systems that deliver a saline flush to remove residual 82Rb from the system downstream of the generator, and preferably deliver the removed residual 82Rb to the patient. Other disclosed systems measure the total volume of saline that flows through a 82Sr/82Rb generator, a total volume of saline that flows through the generator and through a bypass line, or a total volume of saline received by a waste reservoir, in order to monitor system components so that optimal system functioning is assured.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES (Canada)
Inventeur(s)
Sun, Louise
Abrégé
Systems and methods for managing health related resources. A length of stay (LOS) module and a waitlist module receive patient data from a database and, based on at least this data, determine probabilities for one or more patients. For the LOS module, the probability of staying for less than 2 days or more than 7 days after a specific type of surgical procedure is determined. For the waitlist module, the probability of the patient dying or becoming hospitalized within a specific amount of time while on a waiting list is determined. These probabilities are then used by a resource management module to adjust or reallocate health related resources such as critical care slots or surgical procedure scheduling.
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Ruel, Marc
Suuronen, Erik
Alarcon, Emilio
Abrégé
Provided herein are biocompatible and/or biodegradable hydrogel compositions comprising native collagen and chondroitin sulfate, the collagen and chondroitin sulfate being chemically cross-linked thereby forming a matrix. The native collagen may comprise recombinant human collagen type I (rHCI), recombinant human collagen type III (rHCIII), or a combination thereof, for example. Methods and uses thereof for regeneration or repair of tissue, improvement of tissue function, mechanical stabilization of tissue, prevention of tissue damage, or prevention of tissue loss of function are described, particularly with respect to cardiac tissue and myocardial infarction events.
Ottawa Heart Institute Research Corporation (Canada)
L'Institut de Cardiologie de Montréal (Canada)
Inventeur(s)
Vigneault, Patrick
Davis, Darryl
Nattel, Stanley
Parent, Sandrine
Abrégé
+ channel, and methods of producing same. There is also disclosed a method of producing engineered EDCs having a modulated bioelectric property, the method comprising: obtaining EDCs; introducing a KCNN4 gene into the EDCs to increase the expression of KCa3.1 channels, to produce engineered EDCs. There is also disclosed a composition for treating or ameliorating a damaged myocardium in a subject, the composition comprising extracellular vesicles isolated from cultures of engineered EDCs. There is also disclosed a method for treating or ameliorating a damaged myocardium in a subject, comprising administering the engineered EDCs or the extracellular vesicles isolated from cultures of engineered EDCs to the damaged myocardium of the subject.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
C12P 1/00 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes
Disclosed are methods of radioisotope infusion comprising infusing saline comprising a diagnostic dose of a radioisotope, and delivering a pre-measured volume of push saline. The disclosed methods confer improved image quality with low background noise, higher signal to noise ratio (SNR) and higher contrast to noise ratio (CNR), leading to better diagnosis and thus eliminating the need of repeating the infusion and imaging which in turn reduces exposure of a patient to radiation.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Ruel, Marc
Suuronen, Erik
Alarcon, Emilio
Abrégé
Provided herein are biocompatible and/or biodegradable hydrogel compositions comprising native collagen and chondroitin sulfate, the collagen and chondroitin sulfate being chemically cross-linked thereby forming a matrix. The native collagen may comprise recombinant human collagen type I (rHCI), recombinant human collagen type III (rHCIII), or a combination thereof, for example. Methods and uses thereof for regeneration or repair of tissue, improvement of tissue function, mechanical stabilization of tissue, prevention of tissue damage, or prevention of tissue loss of function are described, particularly with respect to cardiac tissue and myocardial infarction events.
A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Lefort, Étienne
Teoli, Vincenzo
Dekemp, Robert A.
Klein, Ran
Abrégé
Provided are 82Sr/82Rb elution systems that accept patient weight as a input function in order to determine an optimal quantity of radioactive rubidium-82 for delivery to a patient pursuant to an imaging scan. Also disclosed are systems that deliver a saline flush to remove residual 82Rb from the system downstream of the generator, and preferably deliver the removed residual 82Rb to the patient. Other disclosed systems measure the total volume of saline that flows through a 82Sr/82Rb generator, a total volume of saline that flows through the generator and through a bypass line, or a total volume of saline received by a waste reservoir, in order to monitor system components so that optimal system functioning is assured.
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
Insulin-like growth factor-binding protein 7 (IGFBP7) has been identified herein as a therapeutic target for the treatment or prevention of heart diseases, metabolic diseases, and other related disease or conditions. IGFBP7 inhibitors having IGFBP7 expression and/or activity reducing properties are described herein. Treatment methods, and uses, relating to such IGFBP7 inhibitors for the treatment or prevention of heart failure, IGFBP7-related metabolic diseases, and related diseases or conditions are provided.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
25.
Serum-free and xenogen-free human cardiac explant-derived stem cells and uses and methods for the production thereof
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Stewart, Duncan J.
Courtman, David
Mount, Seth
Davis, Darryl
Abrégé
Methods for generating serum-free and/or xenogen-free cardiac explant-derived stem cells (EDC) are provided. These methods may include providing an initial cardiac explant, which has been minced and digested; plating the initial cardiac explant; culturing the plated cardiac explant in serum-free and xenogen-free medium; harvesting EDC cells surrounding or emerging from the plated cardiac explant; and optionally performing static expansion of harvested EDC cells in serum-free and xenogen-free media. Serum-free and/or xenogen-free cardiac EDC cells produced by these methods, as well as methods and uses thereof for the treatment of heart failure in a subject in need thereof, are also provided.
THE OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Lemay, Matthieu Olivier
Rubens, Fraser Douglas
Abrégé
A tension-limiting temporary epicardial pacing wire extraction system provides an alternative to current temporary epicardial pacing wire extraction methods in order to reduce the risk of severe complications that may result from variable and excessive tension being applied to the wire during manual extraction. The epicardial pacing wire extraction system includes a housing that houses a motor, a handle for holding the device, a cartridge containing a spool driven by the motor through a coupling for extracting an epicardial pacing wire from a patient, a start/stop button to operate the motor to drive the spool and a cartridge-release mechanism that selectively releases the cartridge from the housing.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Lefort, Étienne
Teoli, Vincenzo
Dekemp, Robert A.
Klein, Ran
Abrégé
Embodiments of the present invention provide for assessing the state of an 82Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 82Rb, 82Sr, or 85Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 82Sr/82Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the 82Rb elution system.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
A61M 36/00 - Application de matériau radioactif au corps
29.
METHODS OF DETECTING AND TREATING CARDIOVASCULAR DISEASES
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Stewart, Alexandre, Francois Roy
Almontashiri, Naif, Ahmad Mahmood
Roberts, Robert
Abrégé
The invention relates to the use of interferon a-21 for detecting the presence of or increased risk of coronary artery disease in a subject positive for a 9p21 risk allele. Diagnostic methods and kits are provided herein for detecting and reducing the risk of cardiovascular disease, including coronary artery disease, in a subject having the 9p21 risk allele by measuring interferon a-21 in the subject. The invention further relates to therapeutic methods which use interfeuron a-21 level to diagnose and treat cardiovascular diseases.
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Dekemp, Robert A.
Klein, Ran
Abrégé
A method of controlling an 82Sr/82Rb elution system having a generator valve for proportioning a flow of saline solution between an 82Sr/82Rb generator and a bypass line coupled to an outlet of the generator such that saline solution traversing the bypass line will merge with eluted saline solution emerging from the generator to provide an active saline solution. During each elution run, a plurality of successive concentration parameter values are obtained at predetermined intervals. Each concentration parameter value is indicative of a respective instantaneous activity concentration of the active saline solution. Respective error values between each concentration parameter value and a target activity concentration value of the elution run are computed. Error data based on a plurality of the computed error values is accumulated. Between successive elution runs, at least one performance parameter of the elution system is adjusted based on the accumulated error data.
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
A61M 36/08 - Blindage du réservoir de fluide, p. ex. blindage de seringue
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Dekemp, Robert A.
Klein, Ran
Abrégé
82Rb generator and a bypass line coupled to an outlet of the generator such that saline solution traversing the bypass line will merge with eluted saline solution emerging from the generator to provide an active saline solution. During each elution run, a plurality of successive concentration parameter values are obtained at predetermined intervals. Each concentration parameter value is indicative of a respective instantaneous activity concentration of the active saline solution. Respective error values between each concentration parameter value and a target activity concentration value of the elution run are computed. Error data based on a plurality of the computed error values is accumulated. Between successive elution runs, at least one performance parameter of the elution system is adjusted based on the accumulated error data.
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Dekemp, Robert, A.
Abrégé
An 82Sr/82Rb generator column is made using a fluid impervious cylindrical container having a cover for closing the container in a fluid tight seal, and further having an inlet for connection of a conduit for delivering a fluid into the container and an outlet for connection of a conduit for conducting the fluid from the container. An ion exchange material fills the container, the ion exchange material being compacted within the container to a density that permits the ion exchange material to be eluted at a rate of at least 5 ml/min at a fluid pressure of 1.5 pounds per square inch (10 kPa). The generator column can be repeatedly recharged with 82Sr. The generator column is compatible with either three-dimensional or two-dimensional positron emission tomography systems.
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Stewart, Duncan J.
Courtman, David
Mount, Seth
Davis, Darryl
Abrégé
Methods for generating serum-free and/or xenogen-free cardiac explant-derived stem cells (EDC) are provided. These methods may comprise steps of providing an initial cardiac explant, which has been minced and digested; plating the initial cardiac explant; culturing the plated cardic explant in serum-free and xenogen-free medium; harvesting EDC cells surrounding or emerging from the plated cardiac explant; and optionally performing static expansion of harvested EDC cells in serum-free and xenogen-free media. Serum-free and/or xenogen-free cardiac EDC cells produced by these methods, as well as methods and uses thereof for the treatment of heart failure in a subject in need thereof, are also provided.
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
JUBILANT DRAXIMAGE INC. (Canada)
Inventeur(s)
Dekemp, Robert A.
Klein, Ran
Lefort, Etienne
Teoli, Vincenzo
Abrégé
Provided are 82Sr/82Rb elution systems that accept patient weight as a input function in order to determine an optimal quantity of radioactive rubidium-82 for delivery to a patient pursuant to an imaging scan. Also disclosed are systems that deliver a saline flush to remove residual 82Rb from the system downstream of the generator, and preferably deliver the removed residual 82Rb to the patient. Other disclosed systems measure the total volume of saline that flows through a 82Sr/82Rb generator, a total volume of saline that flows through the generator and through a bypass line, or a total volume of saline received by a waste reservoir, in order to monitor system components so that optimal system functioning is assured.
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Dekemp, Robert A.
Abrégé
Disclosed are methods of radioisotope infusion comprising infusing saline comprising a diagnostic dose of a radioisotope, and delivering a pre-measured volume of push saline. The disclosed methods confer improved image quality with low background noise, higher signal to noise ratio (SNR) and higher contrast to noise ratio (CNR), leading to better diagnosis and thus eliminating the need of repeating the infusion and imaging which in turn reduces exposure of a patient to radiation.
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
A61M 36/04 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
37.
BIOCOMPATIBLE HYDROGEL COMPOSITIONS AND USES THEREOF
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Suuronen, Erik
Alarcon, Emilio
Ruel, Marc
Abrégé
Provided herein are biocompatible and/or biodegradable hydrogel compositions comprising native collagen and chondroitin sulfate, the collagen and chondroitin sulfate being chemically cross-linked thereby forming a matrix. The native collagen may comprise recombinant human collagen type I (rHCI), recombinant human collagen type III (rHCIII), or a combination thereof, for example. Methods and uses thereof for regeneration or repair of tissue, improvement of tissue function, mechanical stabilization of tissue, prevention of tissue damage, or prevention of tissue loss of function are described, particularly with respect to cardiac tissue and myocardial infarction events.
A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Dekemp, Robert A.
Abrégé
An 82Sr/82Rb generator column is made using a fluid impervious cylindrical container having a cover for closing the container in a fluid tight seal, and further having an inlet for connection of a conduit for delivering a fluid into the container and an outlet for connection of a conduit for conducting the fluid from the container. An ion exchange material fills the container, the ion exchange material being compacted within the container to a density that permits the ion exchange material to be eluted at a rate of at least 5 ml/min at a fluid pressure of 1.5 pounds per square inch (10 kPa). The generator column can be repeatedly recharged with 82Sr. The generator column is compatible with either three-dimensional or two-dimensional positron emission tomography systems.
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
B01D 15/04 - Procédés de séparation comportant le traitement de liquides par des adsorbants ou des absorbants solidesAppareillages pour ces procédés par des substances échangeuses d'ions comme adsorbants
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Dekemp, Robert A.
Klein, Ran
Abrégé
A method of controlling an 82Sr/82Rb elution system having a generator valve for proportioning a flow of saline solution between an 82Sr/82Rb generator and a bypass line coupled to an outlet of the generator such that saline solution traversing the bypass line will merge with eluted saline solution emerging from the generator to provide anactive saline solution. During each elution run, aplurality of successive concentration parameter values areobtained at predetermined intervals. Each concentrationparameter value is indicative of a respective instantaneous activity concentration of the active saline solution. Respective error values between each concentration parameter value and a target activity concentration valueof the elution run are computed. Error data based on aplurality of the computed error values is accumulated. Between successive elution runs, at least one performance parameter of the elution system is adjusted based on the accumulated error data.
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
JUBILANT DRAXIMAGE INC. (Canada)
Inventeur(s)
Dekemp, Robert A.
Klein, Ran
Lefort, Etienne
Teoli, Vincenzo
Abrégé
Embodiments of the present invention provide for assessing the state of an 82Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 82Rb, 82Sr, or 85Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 82Sr/82Rb generator of the system may be halted so as to prevent a user from perfomiing an end-run around these quality control mechanisms of the 82Rb elution system.
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
A61M 36/00 - Application de matériau radioactif au corps
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Dekemp, Robert A.
Klein, Ran
Teoli, Vincenzo
Lefort, Etienne
Abrégé
Embodiments of the present invention provide for assessing the state of an 82Rb elution system. In certain embodi-ments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a conceffiration of 82Rb, 82Sr, or 85Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pm; - sure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 82Sr/82Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the nRb elution system.
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
G01T 1/17 - Dispositions de circuits non adaptés à un type particulier de détecteur
G01T 1/30 - Mesure de la période d'une substance radioactive
G05D 21/02 - Commande des variables chimiques ou physico-chimiques, p. ex. de la valeur du pH caractérisée par l'utilisation de moyens électriques
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Sun, Louise
Abrégé
Systems and methods for managing health related resources. A length of stay (LOS) module and a waitlist module receive patient data from a database and, based on at least this data, determine probabilities for one or more patients. For the LOS module, the probability of staying for less than 2 days or more than 7 days after a specific type of surgical procedure is determined. For the waitlist module, the probability of the patient dying or becoming hospitalized within a specific amount of time while on a waiting list is determined. These probabilities are then used by a resource management module to adjust or reallocate health related resources such as critical care slots or surgical procedure scheduling.
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
SIEMENS MEDICAL SOLUTIONS USA, INC. (USA)
Inventeur(s)
Casey, Michael E.
Dekemp, Robert
Abrégé
A system and method include acquisition of emission data from an object while a radioactive tracer is present in the object, determination of first parameters of a first Gaussian distribution representing a positron range distribution of the radioactive tracer, determination of second parameters of a second Gaussian distribution associated with imaging characteristics of the imaging system, generation of a system matrix based on the first parameters and the second parameters, reconstruction of a three-dimensional image based on the emission data and the system matrix, and display of the three-dimensional image.
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
JUBILANT DRAXIMAGE INC. (Canada)
Inventeur(s)
Dekemp, Robert A.
Klein, Ran
Teoli, Vincenzo
Lefort, Etienne
Abrégé
ABSTRACT Embodiments of the present invention provide for assessing the state of an 'Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 'Rb, 'Sr, or "Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 825r/82Rb generator of the system may be halted so as to prevent a user from perfomiing an end-run around these quality control mechanisms of the 'Rb elution system. Date Recue/Date Received 2020-07-06
OTTAWA HEART INSTITUTE RESEARCH CORPORATION (Canada)
Inventeur(s)
Dekemp, Robert A.
Abrégé
The present invention provides an improved method of PET imaging in a subject for diagnosis and/or treatment of cardiovascular related disease. The method comprises exponential function dosing based on subject body habitus. It provides improved and consistent imaging quality in comparison to fixed or linear dosing based on subject's body weight.
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p. ex. sur la position ou la section du faisceauMesure de la distribution spatiale de radiations